CER-1236

· CERo Therapeutics Holdings, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CER-1236, covering 2026-03-27 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) [Phase 1]

See pricing